Hyperuricemia as a Novel Risk Factor for Colorectal Adenomatous Polyp

Jung Won Lee; Jong Pil Im

doi:10.4166/kjg.2015.66.4.183

Journal List > Korean J Gastroenterol > v.66(4) > 1007423

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee and Im: Hyperuricemia as a Novel Risk Factor for Colorectal Adenomatous Polyp

Editorial

Korean J Gastroenterol 2015;66(4):183-185.

Published online: 4 October 2015

DOI: https://doi.org/10.4166/kjg.2015.66.4.183

Hyperuricemia as a Novel Risk Factor for Colorectal Adenomatous Polyp

Jung Won Lee, Jong Pil Im

Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea

Correspondence to: Jong Pil Im, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno- gu, Seoul 03080, Korea. Tel: +82-2-2072-0638, Fax: +82-2-762-9662, E-mail: jpim0911@snu.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Uric Acid Is a Risk Indicator for Metabolic Syndrome-Related Colorectal Adenoma: Results in a Korean Population Receiving Screening Colonoscopy

References

1. Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015; 47:127–141.

2. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015; 64:1637–1649.

3. Schoen RE, Razzak A, Yu KJ, et al. Incidence and mortality of colorectal cancer in individuals with a family history of colorectal cancer. Gastroenterology. 2015. DOI: doi:10.1053/j.gastro.2015.07.055. [Epub ahead of print].

4. Heitman SJ, Ronksley PE, Hilsden RJ, Manns BJ, Rostom A, Hemmelgarn BR. Prevalence of adenomas and colorectal cancer in average risk individuals: a systematic review and metaanalysis. Clin Gastroenterol Hepatol. 2009; 7:1272–1278.

5. Williams AR, Balasooriya BA, Day DW. Polyps and cancer of the large bowel: a necropsy study in Liverpool. Gut. 1982; 23:835–842.

6. Pendergrass CJ, Edelstein DL, Hylind LM, et al. Occurrence of colorectal adenomas in younger adults: an epidemiologic necropsy study. Clin Gastroenterol Hepatol. 2008; 6:1011–1015.

7. Ben Q, An W, Jiang Y, et al. Body mass index increases risk for colorectal adenomas based on metaanalysis. Gastroenterology. 2012; 142:762–772.

8. Nam SY, Kim BC, Han KS, et al. Abdominal visceral adipose tissue predicts risk of colorectal adenoma in both sexes. Clin Gastroenterol Hepatol. 2010; 8:443–450. e1-e2.

9. Jorgensen B, Knudtson J. Stop cancer colon. Colorectal cancer screening–updated guidelines. S D Med. 2015. Spec No:82–87.

10. Wolin KY, Yan Y, Colditz GA. Physical activity and risk of colon adenoma: a metaanalysis. Br J Cancer. 2011; 104:882–885.

11. Liu CS, Hsu HS, Li CI, et al. Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol. 2010; 10:51.

12. Stocks T, Lukanova A, Bjørge T, et al. Metabolic Syndrome Cancer Project Me-Can Group. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer. 2011; 117:2398–2407.

13. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010; 6:30–38.

14. Neogi T. Clinical practice. Gout. N Engl J Med. 2011; 364:443–452.

15. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension. 2005; 45:18–20.

16. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008; 359:1811–1821.

17. Wang YY, Lin SY, Lai WA, Liu PH, Sheu WH. Association between adenomas of rectosigmoid colon and metabolic syndrome features in a Chinese population. J Gastroenterol Hepatol. 2005; 20:1410–1415.

18. Kim HJ, Kim JE, Jung JH, et al. Uric acid is a risk indicator for metabolic syndrome-related colorectal adenoma: results in a Korean population receiving screening colonoscopy. Korean J Gastroenterol. 2015; 66:202–208.

19. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a metaanalysis. JAMA. 2006; 295:74–80.

20. Cai H, Zhang G, Wang Z, Luo Z, Zhou X. Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and metaanalysis. PLoS One. 2015; 10:e0126944.

21. Makar GA, Holmes JH, Yang YX. Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst. 2014; 106:djt374.

TOOLS

Similar articles